Literature DB >> 27020088

Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells.

Amina Kariminia1, Shernan G Holtan2, Sabine Ivison1, Jacob Rozmus1, Marie-Josée Hebert3, Paul J Martin4, Stephanie J Lee4, Daniel Wolff5, Peter Subrt1, Sayeh Abdossamadi1, Susanna Sung1, Jan Storek6, Megan Levings1, Mahmoud Aljurf7, Mukta Arora2, Corey Cutler8, Geneviève Gallagher9, John Kuruvilla10, Jeff Lipton10, Thomas J Nevill11, Laura F Newell12, Tony Panzarella10, Joseph Pidala13, Gizelle Popradi14, David Szwajcer15, Jason Tay16, Cynthia L Toze11, Irwin Walker17, Stephen Couban18, Barry E Storer4, Kirk R Schultz1.   

Abstract

Chronic graft-versus-host disease (cGVHD) remains one of the most significant long-term complications after allogeneic blood and marrow transplantation. Diagnostic biomarkers for cGVHD are needed for early diagnosis and may guide identification of prognostic markers. No cGVHD biomarker has yet been validated for use in clinical practice. We evaluated both previously known markers and performed discovery-based analysis for cGVHD biomarkers in a 2 independent test sets (total of 36 cases ≤1 month from diagnosis and 31 time-matched controls with no cGVHD). On the basis of these results, 11 markers were selected and evaluated in 2 independent replication cohorts (total of 134 cGVHD cases and 154 controls). cGVHD cases and controls were evaluated for several clinical covariates, and their impact on biomarkers was identified by univariate analysis. The 2 replications sets were relatively disparate in the biomarkers they replicated. Only sBAFF and, most consistently, CXCL10 were identified as significant in both replication sets. Other markers identified as significant in only 1 replication set included intercellular adhesion molecule 1 (ICAM-1), anti-LG3, aminopeptidase N, CXCL9, endothelin-1, and gelsolin. Multivariate analysis found that all covariates evaluated affected interpretation of the biomarkers. CXCL10 had an increased significance in combination with anti-LG3 and CXCL9, or inversely with CXCR3(+)CD56(bright) natural killer (NK) cells. There was significant heterogeneity of cGVHD biomarkers in a large comprehensive evaluation of cGVHD biomarkers impacted by several covariates. Only CXCL10 strongly correlated in both replication sets. Future analyses for plasma cGVHD biomarkers will need to be performed on very large patient groups with consideration of multiple covariates.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27020088      PMCID: PMC4911864          DOI: 10.1182/blood-2015-09-668251

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

1.  Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma.

Authors:  Michael A Kuzyk; Derek Smith; Juncong Yang; Tyra J Cross; Angela M Jackson; Darryl B Hardie; N Leigh Anderson; Christoph H Borchers
Journal:  Mol Cell Proteomics       Date:  2009-05-01       Impact factor: 5.911

2.  Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells plays a major role in the pathogenesis of chronic GVHD.

Authors:  Joanne E Croudace; Charlotte F Inman; Ben E Abbotts; Sandeep Nagra; Jane Nunnick; Prem Mahendra; Charles Craddock; Ram Malladi; Paul A H Moss
Journal:  Blood       Date:  2012-09-25       Impact factor: 22.113

3.  Donor interleukin-22 and host type I interferon signaling pathway participate in intestinal graft-versus-host disease via STAT1 activation and CXCL10.

Authors:  B Lamarthée; F Malard; C Gamonet; C Bossard; M Couturier; J-C Renauld; M Mohty; P Saas; B Gaugler
Journal:  Mucosal Immunol       Date:  2015-07-08       Impact factor: 7.313

4.  Favorable impact of natural killer cell reconstitution on chronic graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation.

Authors:  Vissal David Kheav; Marc Busson; Catherine Scieux; Régis Peffault de Latour; Guitta Maki; Philippe Haas; Marie-Christine Mazeron; Maryvonnick Carmagnat; Emeline Masson; Aliénor Xhaard; Marie Robin; Patricia Ribaud; Nicolas Dulphy; Pascale Loiseau; Dominique Charron; Gérard Socié; Antoine Toubert; Hélène Moins-Teisserenc
Journal:  Haematologica       Date:  2014-08-01       Impact factor: 9.941

5.  Plasma endothelin-1 levels after stem cell transplantation.

Authors:  J F Tomis; C Sanz-Rodriguez; V G de Soria; P Font; S Sánchez; E Gruss; A Figuera; J M Fernández-Rañada
Journal:  Bone Marrow Transplant       Date:  2000-12       Impact factor: 5.483

6.  Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease.

Authors:  Areej El-Jawahri; Joseph Pidala; Yoshi Inamoto; Xiaoyu Chai; Nandita Khera; William A Wood; Corey Cutler; Mukta Arora; Paul A Carpenter; Jeanne Palmer; Mary Flowers; Daniel Weisdorf; Steven Pavletic; Samantha Jaglowski; Madan Jagasia; Stephanie J Lee; Yi-Bin Chen
Journal:  Biol Blood Marrow Transplant       Date:  2014-05-09       Impact factor: 5.742

7.  Burden of morbidity in 10+ year survivors of hematopoietic cell transplantation: report from the bone marrow transplantation survivor study.

Authors:  Can-Lan Sun; John H Kersey; Liton Francisco; Saro H Armenian; K Scott Baker; Daniel J Weisdorf; Stephen J Forman; Smita Bhatia
Journal:  Biol Blood Marrow Transplant       Date:  2013-04-10       Impact factor: 5.742

8.  Plasma CXCL9 elevations correlate with chronic GVHD diagnosis.

Authors:  Carrie L Kitko; John E Levine; Barry E Storer; Xiaoyu Chai; David A Fox; Thomas M Braun; Daniel R Couriel; Paul J Martin; Mary E Flowers; John A Hansen; Lawrence Chang; Megan Conlon; Bryan J Fiema; Rachel Morgan; Prae Pongtornpipat; Kelly Lamiman; James L M Ferrara; Stephanie J Lee; Sophie Paczesny
Journal:  Blood       Date:  2013-12-20       Impact factor: 22.113

9.  Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group.

Authors:  Hisaki Fujii; Geoff Cuvelier; Kevin She; Soudabeh Aslanian; Hiromi Shimizu; Amina Kariminia; Mark Krailo; Zhengjia Chen; Rob McMaster; Axel Bergman; Frederick Goldman; Stephen A Grupp; Donna A Wall; Andrew L Gilman; Kirk R Schultz
Journal:  Blood       Date:  2007-10-09       Impact factor: 22.113

10.  High levels of B-cell activating factor in patients with active chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Kristen E Stevenson; Haesook T Kim; Nazmim S Bhuiya; Corey S Cutler; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Clin Cancer Res       Date:  2007-10-15       Impact factor: 12.531

View more
  37 in total

Review 1.  The search for drug-targetable diagnostic, prognostic and predictive biomarkers in chronic graft-versus-host disease.

Authors:  Hong-Gang Ren; Djamilatou Adom; Sophie Paczesny
Journal:  Expert Rev Clin Immunol       Date:  2018-04-19       Impact factor: 4.473

Review 2.  Biomarkers for posttransplantation outcomes.

Authors:  Sophie Paczesny
Journal:  Blood       Date:  2018-04-05       Impact factor: 22.113

3.  Low-dose IL-2 induces CD56bright NK regulation of T cells via NKp44 and NKp46.

Authors:  S T Loughran; P A Power; S L McQuaid; P Maguire; A Szczygiel; P A Johnson
Journal:  Clin Exp Immunol       Date:  2020-02-13       Impact factor: 4.330

4.  Dickkopf-related protein 3 is a novel biomarker for chronic GVHD after allogeneic hematopoietic cell transplantation.

Authors:  Yoshihiro Inamoto; Paul J Martin; Stephanie J Lee; Amin A Momin; Laura Tabellini; Lynn E Onstad; Joseph Pidala; Mary E D Flowers; Richard L Lawler; Hiroyuki Katayama; Samir Hanash; John A Hansen
Journal:  Blood Adv       Date:  2020-06-09

5.  CXCL10: most consistent cGVHD biomarker?

Authors:  Sophie Paczesny; Mohammad Abu Zaid
Journal:  Blood       Date:  2016-06-16       Impact factor: 22.113

6.  Biomarkers in chronic graft-versus-host disease: quo vadis?

Authors:  D Wolff; H Greinix; S J Lee; T Gooley; S Paczesny; S Pavletic; F Hakim; F Malard; M Jagasia; A Lawitschka; J A Hansen; D Pulanic; E Holler; A Dickinson; E Weissinger; M Edinger; S Sarantopoulos; K R Schultz
Journal:  Bone Marrow Transplant       Date:  2018-01-24       Impact factor: 5.483

Review 7.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

8.  Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease.

Authors:  Frances T Hakim; Sarfraz Memon; Ping Jin; Matin M Imanguli; Huan Wang; Najibah Rehman; Xiao-Yi Yan; Jeremy Rose; Jacqueline W Mays; Susan Dhamala; Veena Kapoor; William Telford; John Dickinson; Sean Davis; David Halverson; Haley B Naik; Kristin Baird; Daniel Fowler; David Stroncek; Edward W Cowen; Steven Z Pavletic; Ronald E Gress
Journal:  J Immunol       Date:  2016-09-30       Impact factor: 5.422

9.  Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.

Authors:  Mohammad Abu Zaid; Juan Wu; Cindy Wu; Brent R Logan; Jeffrey Yu; Corey Cutler; Joseph H Antin; Sophie Paczesny; Sung Won Choi
Journal:  Blood       Date:  2016-11-08       Impact factor: 22.113

10.  Comprehensive B Cell Phenotyping Profile for Chronic Graft-versus-Host Disease Diagnosis.

Authors:  Jacob Rozmus; Amina Kariminia; Sayeh Abdossamadi; Barry E Storer; Paul J Martin; Stephanie J Lee; Daniel Wolff; Mukta Arora; Corey Cutler; Kirk R Schultz
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.